clinical trial · NCT06660368
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 52
Relapsed or Refractory Acute Myeloid Leukemia (AML)Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimenVenetoclax
brief summary
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
started
Nov 26, 2024
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Apr 1, 2026
official title
A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol